| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In vitro aggregation of wild-type α-synuclein and its well-known mutations A30P and H50Q is greatly reduced in a substoichiometric molar ratio by SynuClean-D. In protein-misfolding cyclic amplification tests, SynuClean-D inhibits fibril propagation and reduces the amount of mature α-synuclein fibrils. According to computational research, SynuClean-D can bind to cavities in mature α-synuclein fibrils and does indeed exhibit a substantial fibril disaggregation activity[1].
|
|---|---|
| ln Vivo |
Two Caenorhabditis elegans models of Parkinson's disease (PD) that express α-synuclein in either muscle or dopaminergic neurons show a significant reduction in α-synuclein toxicity after treatment with SynuClean-D. In worms treated with SynuClean-D, there is a reduction in α-synuclein aggregation in the muscle and a corresponding recovery of motility. What's more, this substance can prevent α-synuclein-induced degeneration in dopaminergic neurons[1].
|
| References |
| Molecular Formula |
C13H5F3N4O5
|
|---|---|
| Molecular Weight |
354.197812795639
|
| Exact Mass |
354.021
|
| CAS # |
685121-45-3
|
| PubChem CID |
2726228
|
| Appearance |
White to yellow solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
25
|
| Complexity |
750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1=C(C#N)C(NC(C2C=CC=C(C=2)[N+](=O)[O-])=C1[N+](=O)[O-])=O)(F)F
|
| InChi Key |
OJRLTEJFYMZKQB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H5F3N4O5/c14-13(15,16)9-8(5-17)12(21)18-10(11(9)20(24)25)6-2-1-3-7(4-6)19(22)23/h1-4H,(H,18,21)
|
| Chemical Name |
5-nitro-6-(3-nitrophenyl)-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 83.33 mg/mL (235.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8233 mL | 14.1163 mL | 28.2326 mL | |
| 5 mM | 0.5647 mL | 2.8233 mL | 5.6465 mL | |
| 10 mM | 0.2823 mL | 1.4116 mL | 2.8233 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
